This invention relates to new pharmaceutical formulations, and to new medical uses, of gabapentin and pregabalin. The formulations may comprise up to three components including an immediate release component, a sustained release component and a delayed release component. The proportion of each component in the formulation may be adjusted to achieve the desired AUC and therapeutic effect following oral administration in a human subject.
